ALSの予後は個人差が非常に大きく、予後予測ができればより個人個人に合った治療が選択できるであろうということで、予後予測因子を同定するための研究が盛んです。ＡＬＳの進行の度合いを評価するスコアとして、ALS機能評価尺度（ALSFRS‐R）が良く使われます。
ALSの予後予測マーカーに関するレビュー論文
- Are Circulating Cytokines Reliable Biomarkers for Amyotrophic Lateral Sclerosis? Int. J. Mol. Sci. 2019, 20(11), 2759; https://doi.org/10.3390/ijms20112759 Interleukins comprise of a large family of cytokines that can exert both pro-inflammatory and anti-inflammatory actions. They are mainly synthesized by T cells, macrophages and endothelial cells promoting the development and differentiation of T and B cells, and hematopoietic cells. Numerous interleukins have been found elevated in CSF and/or blood from ALS patients compared to the levels measured in controls and/or patients with other non-inflammatory neurological disorders (OND): IL-1Ra, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, IL-17A, IL-18 and IL-21.
- Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis Lucas T. Vu & Robert Bowser Neurotherapeutics volume 14, pages119–134(2017) Published: 08 December 2016
ALSのバイオマーカー、予後予測因子に関する論文
- Longitudinal biomarkers in amyotrophic lateral sclerosis 09 June 2020 https://doi.org/10.1002/acn3.51078 Annals of Clinical and Translational Neurology Volume7, Issue7 July 2020 Pages 1103-1116
- Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Sci Rep. 2020; 10: 5941. Published online 2020 Apr 3. doi: 10.1038/s41598-020-62756-8
- Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R358Ala variant groups in amyotrophic lateral sclerosis patients Marlena Wosiski-Kuhn,James B. Caress,Michael S. Cartwright,Gregory A. Hawkins &Carol Milligan Received 22 Feb 2020, Accepted 18 Aug 2020, Published online: 14 Sep 2020 Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Development and validation of a 1-year survival prognosis estimation model for Amyotrophic Lateral Sclerosis using manifold learning algorithm UMAP Vincent Grollemund, Gaétan Le Chat, Marie-Sonia Secchi-Buhour, François Delbot, Jean-François Pradat-Peyre, Peter Bede & Pierre-François Pradat Scientific Reports volume 10, Article number: 13378 (2020)
- Does including machine learning predictions in ALS clinical trial analysis improve statistical power? Nina Zhou Paul Manser First published: 30 August 2020 ANNALS of Clinical and Translational Neurology The three candidate models were RF, super learner (SL), and a linear mixed effects model with random intercepts (LME).
- Model-Based and Model-Free Techniques for Amyotrophic Lateral Sclerosis Diagnostic Prediction and Patient Clustering. Neuroinformatics, 01 Jul 2019, 17(3):407-421
- Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. VOLUME 17, ISSUE 5, P423-433, MAY 01, 2018 THE LANCET Neurology (本文は有料）a repository copy
- Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis JAMA Neurol. 2017;74(6):660-667.
- JaCALS ALS の進行，予後規定因子 臨床神経 2011;51:903-905 発症から各エンドポイントまでの期間に影響する因子として，性別，発症年齢，病型，入院治療を要する外傷歴の有無， 全身麻酔を要する手術歴の有無，喫煙歴の有無，改訂版 El Escorial 診断基準適合度を候補として，単変量解析（Log-rank test）でスクリーニングをおこない，p 値が 0.05 を下回った因 子について Cox 比例ハザードモデルをもちいた多変量解析 をおこなった．
ALSFRS-R
- 筋萎縮性側索硬化症機能評価スケール改訂版 （ALSFRS-R：ALS Functional Rating Scale-Revised）
- ALSFRS-R
ＡＬＳの予後予測因子
- 病型，病態，病因，経過（予後） 神経内科Clinical Questions & Pearls 運動ニューロン疾患 鈴木則宏 シリーズ監修 ／ 青木正志 編集 http://chugaiigaku.jp/ 発症部位に規定される病型が経過，予後に影響することは数多くのコホートスタディによって示されている． … 発症年齢は進行・予後を左右する因子
参考記事
- 筋萎縮性側索硬化症（ALS）のリハビリテーション治療 Jpn J Rehabil Med 2018；55：539-544
